ELVN
Enliven Therapeutics Inc
NASDAQ · Pharmaceuticals
$29.42
+2.43 (+9.00%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 263.34M | 235.73M | 210.63M |
| Net Income | 79.58M | 63.75M | 57.56M |
| EPS | — | — | — |
| Profit Margin | 30.2% | 27.0% | 27.3% |
| Rev Growth | -0.5% | +12.7% | -7.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 261.38M | 238.05M | 246.29M |
| Total Equity | 620.63M | 551.15M | 566.73M |
| D/E Ratio | 0.42 | 0.43 | 0.43 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 141.73M | 119.11M | 111.32M |
| Free Cash Flow | 52.28M | 61.02M | 35.31M |